C Heading

Summary

Affiliation: University Hospital Aintree
Country: UK

Publications

  1. ncbi Conus peptides and neuroprotection
    Christine E Heading
    Department of Biological Sciences, The Open University, Milton Keynes, UK
    Curr Opin Investig Drugs 3:915-20. 2002
  2. ncbi Siramesine H Lundbeck
    C Heading
    Curr Opin Investig Drugs 2:266-70. 2001
  3. ncbi Recent advances against substance abuse
    Christine E Heading
    The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes, MK7 6AA, UK
    IDrugs 6:681-7. 2003
  4. ncbi NicVAX (Nabi Biopharmaceuticals)
    Christine E Heading
    The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes MK7 6AA, UK
    IDrugs 6:1178-81. 2003
  5. ncbi Conus toxins: targets and properties
    Christine E Heading
    The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes, MK7 6AA UK
    IDrugs 7:1011-6. 2004
  6. ncbi Vivitrex (Alkermes/Cephalon)
    Christine E Heading
    Faculty of Science, The Open University in the North, Eldon House, Regent Centre, Gosforth, Newcastle upon Tyne NE3 3PW, UK
    Curr Opin Investig Drugs 7:81-8. 2006
  7. ncbi Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction
    Christine E Heading
    The Open University in the North, Faculty of Science, Eldon House, Regent Centre, Gosforth, Newcastle upon Tyne NE3 3PW, UK
    Curr Opin Investig Drugs 8:71-7. 2007
  8. ncbi Gender issues and the pharmacotherapy of substance abuse
    Christine E Heading
    Faculty of Science, The Open University in the North, Eldon House Regent Centre, Gosforth, Newcastle upon Tyne, NE3 3PW, UK
    IDrugs 11:428-32. 2008

Detail Information

Publications8

  1. ncbi Conus peptides and neuroprotection
    Christine E Heading
    Department of Biological Sciences, The Open University, Milton Keynes, UK
    Curr Opin Investig Drugs 3:915-20. 2002
    ..The poor pharmacokinetic profile of the peptides remains a challenge...
  2. ncbi Siramesine H Lundbeck
    C Heading
    Curr Opin Investig Drugs 2:266-70. 2001
    ..Phase III trials are expected to take place in 2002 [387270]. A series of compounds have been synthesized by Lundbeck, the most potent of which may serve as a backup compound [179036]...
  3. ncbi Recent advances against substance abuse
    Christine E Heading
    The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes, MK7 6AA, UK
    IDrugs 6:681-7. 2003
    ..For cocaine abuse, the main focus is on products targeting the dopamine reuptake system...
  4. ncbi NicVAX (Nabi Biopharmaceuticals)
    Christine E Heading
    The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes MK7 6AA, UK
    IDrugs 6:1178-81. 2003
    ..Nabi Biopharmaceuticals is developing NicVAX, a proprietary vaccine designed as a potential therapeutic to prevent and treat nicotine addiction...
  5. ncbi Conus toxins: targets and properties
    Christine E Heading
    The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes, MK7 6AA UK
    IDrugs 7:1011-6. 2004
    ..In turn, this presents problems of bioavailability, while the potency is a potential source of toxicity...
  6. ncbi Vivitrex (Alkermes/Cephalon)
    Christine E Heading
    Faculty of Science, The Open University in the North, Eldon House, Regent Centre, Gosforth, Newcastle upon Tyne NE3 3PW, UK
    Curr Opin Investig Drugs 7:81-8. 2006
    ..Alkermes and Cephalon are currently awaiting Food and Drug Administration review of the Vivitrex new drug application, which was granted Priority Review in May 2005...
  7. ncbi Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction
    Christine E Heading
    The Open University in the North, Faculty of Science, Eldon House, Regent Centre, Gosforth, Newcastle upon Tyne NE3 3PW, UK
    Curr Opin Investig Drugs 8:71-7. 2007
    ..A phase II trial was initiated in Switzerland in January 2005 and in February 2006, Cytos Biotechnology announced that it planned to begin a phase IIb/III trial in 2007...
  8. ncbi Gender issues and the pharmacotherapy of substance abuse
    Christine E Heading
    Faculty of Science, The Open University in the North, Eldon House Regent Centre, Gosforth, Newcastle upon Tyne, NE3 3PW, UK
    IDrugs 11:428-32. 2008
    ..Some gender differences will have more clinical significance than others, but any difference related to gender has the potential to complicate clinical trials and other studies...